Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM. INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematologic effects. Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in the United States.
Sodium Channel Inhibitors Related Products:
Carbamazepine; A-803467; Camostat Mesilate; Ambroxol hcl; Proparacaine hydrochloride; Rufinamide; Zonisamide; Zonisamide sodium salt; Dronedarone hcl; Levobupivacaine; Levobupivacaine hcl; Vinpocetine; Propafenone hcl; Lamotrigine